The EU will first have to pass legislation reducing U.S. export tariffs to zero in order to get the 27.5% tariffs on car exports reduced to 15%.

Pharmaceutical importers are navigating one of the most volatile trade environments in recent memory.

By all means, consider embracing technology to supercharge all aspects of your supply chain. But never underestimate the power of human-driven partnerships to yield the best and most valuable results.

The pharmaceutical industry has long protested the idea of globally linked drug prices as a threat to years of U.S. dominance in biomedical research.

So far, the global economy has held up better than many economists expected after Trump’s initial tariff blitz. That could all be about to change.

Confusion persists over whether 15% tariff will apply to U.S. imports of drugs.

It’s far from clear that the EU and U.S. will be able to iron out all their differences on the many contentious issues yet to deal with.

With global trade frictions and rapid policy shifts set to continue, companies can no longer afford to treat tariffs as a short-term challenge

A number of other drugmakers have rolled out similar plans to ramp up U.S. manufacturing in recent days, in the face of continued pressure from the Trump administration.

Even traditional automation of assigning HS codes, in the form of digitally stored and searchable codes, is of limited utility. Enter artificial intelligence.